Reducing Pain Medication Potency with CBD Isolate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management medications often require high doses of active synthetic ingredients, leading to adverse effects on the human body and risks of addiction and dependence, particularly with opioids, while providing limited relief for severe pain and chronic conditions.
Innovation Solution
A method that combines a small dose of active synthetic pain-management ingredients, such as naproxen, acetaminophen, or ibuprofen, with a designated amount of cannabidiol (CBD) isolate to create a symbiotic blend, reducing the adverse effects and enhancing pain relief without addiction risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of active synthetic ingredients are used in pain management medications, then pain relief effectiveness is improved, but adverse effects on the human body and addiction risks increase
Solution Approach 1:
The patent combines synthetic active ingredients (NSAIDs, acetaminophen, or opioids at reduced doses) with CBD isolate to create a composite pain management composition. This composite formulation allows the synthetic component to provide baseline pain relief while the CBD component amplifies the effect and reduces adverse effects, thereby maintaining effectiveness while reducing harm
Solution Approach 2:
The patent changes the dosage parameter of synthetic active ingredients from approved high doses to one-quarter of the approved dose. This parameter reduction, combined with the addition of CBD isolate, achieves the desired pain relief effectiveness while significantly reducing adverse effects and addiction risks associated with traditional high-dose formulations
2Object-affected harmful factors
If quarter amount of active synthetic ingredient is used in pain management compositions, then adverse effects are reduced, but pain relief effectiveness may be insufficient
Solution Approach 1:
The patent merges the therapeutic effects of reduced-dose synthetic active ingredients with the analgesic and anti-inflammatory properties of CBD isolate. This combination creates a synergistic effect where the two components work together to provide adequate pain relief effectiveness even though the synthetic ingredient dose is reduced to one-quarter of the approved amount
3Reliability
If traditional pain management medications are used, then pain relief is provided, but vulnerability to addiction and dependence increases
Solution Approach 1:
The patent introduces CBD isolate as an intermediary substance that enhances the analgesic effect of reduced-dose synthetic ingredients. This intermediary role of CBD allows the formulation to provide effective pain relief while reducing the required dose of opioid or NSAID components, thereby decreasing vulnerability to addiction and dependence
Data Source
AI summary
A system and method for producing pain-management formulations that amplify and improve the effects of lower doses of the active ingredients in existing pain-management medications is disclosed. Active ingredients in medications are combined in smaller doses, for example, 25% of typical approved or prescribed doses with a natural ingredient used to amplify the effects of the active ingredient without adversely affecting a human's organs. In one embodiment, the combined formulation comprises an active drug ingredient, for example naproxen, combined with a designated amount of a natural ingredient in a symbiotic relationship in a natural USP grade carrier oil to formulate a blended composition that is effective yet safe. The symbiotic relationship between the synthetic and natural ingredients serve to amplify the effects of the active synthetic ingredient for pain management while preventing the adverse effects caused by increased medication potency on a human body's organs.